Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as ...

Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Thousand Oaks, Calif.-based Amgen won a patent dispute against Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron Pharmaceuticals in 2015. Amgen alleged Praluent, which Sanofi and Regeneron co ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.

The U.S. Court of Appeals on Wednesday stayed an order that would bar Regeneron Pharmaceuticals and Sanofi from selling their cholesterol drug Praluent.The drugmakers can continue to sell the ...

Sanofi expects Dupixent to achieve around €22 billion in sales in 2030. Regeneron recorded collaboration revenues of $1.18 billion from Sanofi during the first quarter of 2025, up 30% year over ...

With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...